{
    "patient": {
        "Name": "Jennifer Castillo",
        "DateOfBirth": "1963-12-08",
        "Sex": "Female",
        "Diagnosis": "Acute lymphocytic leukemia (ALL)",
        "BodyPart": "Leukemia",
        "Physician": "Dr. William Martin",
        "TreatingInstitution": "Young, Thomas and Watkins"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Leukemia",
            "CollectedDate": "2024-03-26",
            "ReceivedDate": "2024-03-26",
            "TumorPercentage": "8%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-03-29",
            "ReceivedDate": "2024-03-31"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "KIT",
                "DNA Alteration": "c.1669T>A",
                "GeneMutation": "p.V559D Stopgain-LOF",
                "VariantAlleleFraction": "25.44%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "BRAF",
                "DNA Alteration": "c.1397G>C",
                "GeneMutation": "p.K642E Frameshift-LOF",
                "VariantAlleleFraction": "10.63%"
            },
            {
                "Gene": "BRCA2",
                "DNA Alteration": "c.5946delT",
                "GeneMutation": "p.V600K Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "28.01%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "HRAS"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "9 m/Mb",
            "Tmbpercentile": "43%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.25%"
            },
            {
                "Gene": "ARHGAP45",
                "DNA Alteration": "c.416G>A",
                "GeneMutation": "p.R139H Nonsense-LOF",
                "VariantAlleleFraction": "14.86%"
            },
            {
                "Gene": "GNAS",
                "DNA Alteration": "c.680A>G",
                "GeneMutation": "p.R201H Frameshift-LOF",
                "VariantAlleleFraction": "5.1%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Frameshift-GOF",
                "VariantAlleleFraction": "4.24%"
            },
            {
                "Gene": "CSF1R",
                "DNA Alteration": "c.1085A>G",
                "GeneMutation": "p.H362R Frameshift-LOF",
                "VariantAlleleFraction": "9.17%"
            },
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A374E Spliceregionvariant-GOF",
                "VariantAlleleFraction": "1.1%"
            },
            {
                "Gene": "ERBB2",
                "DNA Alteration": "c.926G>A",
                "GeneMutation": "p.G776C Frameshift-GOF",
                "VariantAlleleFraction": "4.82%"
            },
            {
                "Gene": "H3.3",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G35L Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.72%"
            },
            {
                "Gene": "HBB",
                "DNA Alteration": "c.79G>A",
                "GeneMutation": "p.E7V Spliceregionvariant-GOF",
                "VariantAlleleFraction": "7.18%"
            },
            {
                "Gene": "MET",
                "DNA Alteration": "c.3749T>C",
                "GeneMutation": "p.V1070G Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "2.35%"
            },
            {
                "Gene": "PDGFRA",
                "DNA Alteration": "c.1154_1155delinsTA",
                "GeneMutation": "p.D842V Nonsense-LOF",
                "VariantAlleleFraction": "5.15%"
            },
            {
                "Gene": "SIX1",
                "DNA Alteration": "c.530A>G",
                "GeneMutation": "p.Q177R Spliceregionvariant-LOF",
                "VariantAlleleFraction": "8.91%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "KLF1",
        "MAPK1"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "KIT",
                "DNA Alteration": "c.1669T>A",
                "GeneMutation": "p.V559D Stopgain-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "25.44%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "BRAF",
                "DNA Alteration": "c.1397G>C",
                "GeneMutation": "p.K642E Frameshift-LOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "10.63%"
            },
            {
                "Gene": "BRCA2",
                "DNA Alteration": "c.5946delT",
                "GeneMutation": "p.V600K Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "28.01%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-03-25"
    },
    "other": {
        "ReportId": "3523",
        "ReportDate": "2024-03-29",
        "SignedBy": "William Martin",
        "Supervisor": "Dr. Sean Walton"
    }
}